Is Erdafitinib/Bocco a PARP inhibitor?

Many patients are confused when understanding targeted drugs and lump drugs with different mechanisms of action into one category. In fact, Erdafitinib is not a PARP inhibitor, but an FGFR inhibitor. The two classes of drugs are completely different in mechanism and indications.

PARP inhibitors mainly target the PARP enzyme in the DNA repair mechanism. If cancer cells lack critical DNA repair capabilities after genetic mutations occur, they will rely on the PARP pathway to maintain survival. Inhibiting this pathway makes cancer cells more susceptible to fatal DNA damage, ultimately leading to cell death. Typical PARP inhibitors include olaparib, niraparib, etc., which are commonly used in the treatment of ovarian cancer, breast cancer, and prostate cancer, especially in patients with BRCA gene mutations.

In contrast, erdafitinib targets FGFR2 and FGFR3, receptors that are abnormally active in some tumors, causing cancer cells to continue to divide. Erdafitinib inhibits tumor growth by binding to and inhibiting FGFR and blocking signal transduction. Therefore, from the perspective of mechanism of action, erdafitinib and PARP inhibitors belong to two completely different drug categories.

In terms of indications, erdafitinib is mainly used for patients with locally advanced or metastatic bladder cancer with FGFR gene mutations, rather than BRCA-related tumor types. This means that patients must pass genetic testing to confirm their suitability for erdafitinib before taking the drug. Modern cancer treatment emphasizes "molecular typing" precisely because the efficacy of different drugs varies significantly in different genetic backgrounds.

Therefore, it is important to clearly differentiate between erdafitinib andPARP inhibitors. The former is an FGFR inhibitor, targeting people with FGFR abnormalities such as bladder cancer; the latter is a DNA repair pathway inhibitor, often used in BRCA mutation-related tumors. Although both are targeted therapy drugs, their applicable populations, mechanisms of action, and treatment pathways are completely different.

References：https://www.balversa.com/